Focus

Opthea is committed to improving vision in patients suffering from retinal eye diseases.

We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies.

OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.

LEARN MORE

Disease

Wet AMD is the leading cause of blindness in the developed world in people aged over 50 years. It is caused by the abnormal growth and leakage of blood vessels at the back of the eye, which causes degeneration of the retina and vision loss.

Learn More

Technology

Opthea’s technology is centered on two members of the Vascular Endothelial Growth Factor (VEGF) family of proteins, VEGF-C and VEGF-D, and their activation of VEGF receptors. These proteins promote blood vessel development (angiogenesis) by binding and activating VEGFR-2 and VEGFR-3, and lymphatic vessel development (lymphangiogenesis), by activation of VEGFR-3.

Learn More

Opportunity

Both wet AMD and DME are associated with vascular dysfunction and fluid accumulation at the back of the eye in a region of the central retina or ‘macula’ that is needed for sharp, central vision. Vessel growth and vascular leakage are primarily driven by members of the vascular endothelial growth factor (VEGF) family, which comprises 5 members including VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PlGF).

Learn More

OPT-302

OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Learn More

Clinical Trials

Opthea initiated two pivotal Phase 3 clinical trials for the treatment of wet AMD in the first half of 2021. Opthea has completed a Phase 2b clinical trial investigating OPT-302 in wet AMD patients, and has completed a Phase 1b/2a clinical trial in patients with DME.

Learn more

WITH CLINICAL TRIALS PROGRESSING
AND DATA LOOKING PROMISING,
WE BELIEVE OPT-302 WILL IMPROVE
OUTCOMES FOR PATIENTS WITH
THESE DEBILITATING DISEASES.

Opthea Researcher

Announcements

Opthea Opens Patient Enrollment in the Asia-Pacific Region

19th October 2021

“We are delighted to open enrollment in the Asia-Pacific region. This is a significant milestone for the OPT302 development program and enables eligible patients to participate in the ShORe and COAST Phase 3 trials.

Read More

Opthea Corporate Presentation – October 2021

19th October 2021

OPT-302 has the potential to revolutionize the treatment of wet AMD and improve and preserve vision for millions of patients.

Read More

Opthea Chairman’s Address to the 2021 Annual General Meeting

19th October 2021

Despite the unparalleled circumstance that our nation, our industry, and our company has faced over the past year against the backdrop of a global pandemic, Opthea has advanced significantly.

Read More

Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights

30th August 2021

Despite the continued impact of COVID-19 around the world, our team has continued to make steady progress advancing
our lead program, OPT-302, and strengthening the Company for continued global expansion.

Read More

ALL ANNOUNCEMENTS